News Snapshot:
Eli Lilly 's presentation Tuesday evening at the influential JPMorgan Healthcare Conference was light on near-term financial updates, as expected, but heavy on discussion about the world's most valuable drugmaker's plans to sustain its recent run of successes well into the future. Investors liked what they heard and sent Lilly shares to an all-time high Wednesday. Eli Lilly intends to keep spending heavily, but wisely, on research and development in the coming years, CEO Dave Ricks said after the closing Tuesday, amid what Wall Street widely expects will be a period of blistering topline revenue growth fueled by tirzepatide —...
